A recent retrospective study (S Lega et al. Inflamm Bowel Dis 2019; 25: 134-41) suggests that proactive therapeutic drug monitoring (pTDM) with infliximab (IFX) helps achieve similar outcomes as combination therapy (with immunomodulator) in patients with inflammatory bowel disease.
Before reviewing the key findings, it is important to emphasize a few crucial limitations/methods:
- The study enrolled 83 patients; only 16 received were in the monotherapy pTDM group.
- This was a retrospective study
- The authors utilized TDM at week 10. (week 10 infliximab level). If the IFX level was <20 mcg/mL, the dose and frequency of infliximab were both adjusted. If the level was between 20 & 25, either the frequency was adjusted or no adjustment, and if the level was >25, then no adjustment in dosing was performed.
- The frequency of infliximab discontinuation with mono therapy in those with pTDM was lower than in those with ‘standard of care’ TDM (P=0.04) but did not differ from patients receiving combination therapy
- Overall 9 of the 83 patients (11%) discontinued IFX during the 1-year study
In the discussion, the authors suggest that week 14 TDM may be suboptimal as this is the first time patients have an 8-week interval.
My take: The jury is out with regard to whether pTDM can negate the need for combination therapy –a prospective trial is needed; however, the idea of getting TDM a bit earlier is intriguing, particularly as it has been shown that a high percentage of pediatric patients are receiving an insufficient dose of infliximab (Is Standard Infliximab Dose Tool Low in Pediatrics?)
Key words: 10 weeks, therapeutic drug monitoring, infliximab, trough
Related blog posts:
- Digging into the COMMIT study
- Don’t be Fooled About Withdrawing Immunomodulator Cotherapy -Look Past the Headline
- Methotrexate –First Choice Immunomodulator? | gutsandgrowth
- Should All Pediatric Patients with Crohn’s Disease Continue Combination Therapy? | gutsandgrowth
- ‘Don’t Believe Our Study’ | gutsandgrowth
- Changes in the Use of IBD Biologic Therapy | gutsandgrowth
- Toronto Consensus: Practice Guidelines for Nonhospitalized Ulcerative Colitis | gutsandgrowth
Disclaimer: These blog posts are for educational purposes only. Specific dosing of medications/diets (along with potential adverse effects) should be confirmed by prescribing physician/nutritionist. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.
Pingback: Combination Therapy Study Points to Central Role of Adequate Drug Levels | gutsandgrowth
Pingback: Briefly noted: Induction Infliximab Levels | gutsandgrowth
Pingback: Proactive Therapeutic Drug Monitoring -Different Time Points | gutsandgrowth
Pingback: Combination Therapy Still Works for Inflammatory Bowel Disease (Part 1) | gutsandgrowth
Pingback: Combination Therapy Associated with Treatment Persistence | gutsandgrowth
Pingback: CCFA: Updates in IBD Conference (part 1) | gutsandgrowth
Pingback: Here’s The Proof That Proactive Drug Monitoring Improves Outcomes in Children With Crohn’s Disease | gutsandgrowth
Pingback: IBD Updates December 2019 | gutsandgrowth
Pingback: Expert Guidance on Inflammatory Bowel Disease (Part 2) | gutsandgrowth
Pingback: Proactive Therapeutic Drug Monitoring in Pediatric Crohn’s disease -Better Outcomes | gutsandgrowth
Pingback: How Much Infliximab Can You Give to Young Children? | gutsandgrowth
Pingback: Converting to Monotherapy for Children with Inflammatory Bowel Disease | gutsandgrowth
Pingback: Real-World Experience with Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease | gutsandgrowth
Pingback: Combating Anti-Drug Antibodies with Immunomodulators in Pediatric IBD | gutsandgrowth
Pingback: Preventing Fistulas and Improving Radiologic Remission with Infliximab | gutsandgrowth
Pingback: For the Next Insurance Appeal: Therapeutic Drug Monitoring in Adalimumab Treatment (Pediatrics) & Satire on Prior Authorizations | gutsandgrowth
Pingback: Expert Consensus: New Recommendations for Therapeutic Drug Monitoring | gutsandgrowth
Pingback: Improving Outcomes with Proactive Therapeutic Drug Monitoring + Swiss COVID1- Data | gutsandgrowth
Pingback: Low Anti-TNF Levels or Antibodies Are Associated with Antibodies to Subsequent Anti-TNF Agent | gutsandgrowth